Financial Performance - Net income reached $1.643 billion, with diluted earnings per share at $3.85, reflecting a 10% linked quarter growth and 11% year-over-year growth[32] - Pretax, pre-provision earnings (PPNR) grew by 10% linked quarter and 11% year-over-year[8, 32] - Total revenue increased by 4% linked quarter and 5% year-over-year, reaching $5.661 billion[8, 32] - The company announced a dividend increase of $0.10, or 6%, to $1.70 per common share[8] - Return on average tangible common equity (ROTCE) was 15.6%[8] Balance Sheet - Average loans increased by 2% linked quarter, totaling $322.8 billion, marking the strongest loan growth since 4Q22[8, 13] - Total deposits increased by 1% linked quarter, reaching $423 billion[13] - Common shareholders' equity increased by 3% linked quarter and 13% year-over-year, reaching $50.7 billion[13] Business Segments - Net consumer checking accounts grew by 2% year-over-year, including 6% growth in the Southwest[12] - Brokerage assets increased by 7% year-over-year to a record level of $87 billion[12] - Asset Management fees increased 5% year-over-year to a record first-half level[12] Credit Quality - Nonperforming loans (NPLs) decreased, with the NPL ratio to total loans at 0.65%[39, 41] - Net loan charge-offs (NCOs) also declined, with the NCO ratio to average loans at 0.25%[39, 41] Guidance - The company anticipates average loans to increase by approximately 1% for the full year 2025[44] - Net interest income is expected to increase by approximately 7% for the full year 2025[44] - Fee income is projected to increase by 4% to 5% for the full year 2025[44]

Investor Call SECOND QUARTER 2025 JULY 16, 2025 Time: 8:30 AM CT Webcast: www.pnfp.com (investor relations) M. TERRY TURNER, PRESIDENT AND CEO HAROLD R. CARPENTER, EVP AND CFO Safe Harbor Statements Forward Looking Statements All statements, other than statements of historical fact, included in this presentation, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act o ...

Financial Performance - The company's net revenues for 2Q25 reached $14.58 billion[3], while year-to-date (YTD) net revenues amounted to $29.65 billion[3] - Net earnings for 2Q25 were $3.72 billion[3], and YTD net earnings totaled $8.46 billion[3] - Diluted earnings per share (EPS) for 2Q25 stood at $10.91[3], with a YTD EPS of $25.07[3] - The annualized return on equity (ROE) for 2Q25 was 12.8%[3], and the YTD ROE was 14.8%[3] - The annualized return on tangible equity (ROTE) for 2Q25 was 13.6%[3], with a YTD ROTE of 15.8%[3] Segment Performance - Global Banking & Markets reported net revenues of $10.12 billion for 2Q25, a 24% increase compared to 2Q24[6] - Asset & Wealth Management's net revenues for 2Q25 were $3.778 billion, a 3% decrease compared to 2Q24[6] - Platform Solutions generated net revenues of $685 million for 2Q25, a 2% increase compared to 2Q24[6] Asset & Wealth Management - Assets Under Supervision (AUS) - Total assets under supervision (AUS) reached a record $3.29 trillion[3] - Long-term AUS net inflows were $17 billion[28] - Liquidity products experienced net outflows of $12 billion[28]

Financial Performance - Net income available to common shareholders (NIAC) increased to $233 million, a 27% increase compared to 2Q24[7] - Diluted EPS increased to $045, a 32% increase compared to 2Q24[7] - Adjusted ROTCE was 136%, an increase of 57bps from 1Q25[12] - Adjusted PPNR was $338 million, up 1% from 1Q25[14] Balance Sheet - Period end loans increased by $1 billion from 1Q25, driven by loans to mortgage companies (LMC) seasonality and continuing growth within C&I[10] - Period end deposits increased by $14 billion from 1Q25, reflecting incremental brokered deposits and DDA growth[10] - The loan-to-deposit ratio was 96%, down slightly from 1Q25[10] - Tangible book value per share (TBVPS) increased by $040 to $1357, driven by strong earnings & mark-to-market impact[10] Asset Quality & Capital - CET1 ratio was maintained at 110%, in line with the near-term target[10] - ACL/loans ratio decreased by 3bps to 142%, reflecting loans to mortgage companies (LMC) growth and upgrades[10]

Financial Outlook Update - The company raises its net sales outlook to $31.6 - $31.8 billion[27], representing an increase of 4.3% compared to Fiscal Year 2024 on a 52-week basis[27] - The company anticipates adjusted EBITDA of $535 - $565 million[27], reflecting an increase of 4.3% compared to Fiscal Year 2024 on a 52-week basis[27] - The company projects free cash flow of approximately $200 million[27], a roughly 4.3-times increase compared to Fiscal Year 2024[27] - The company estimates capital and cloud implementation expenditures of around $250 million[27], a decrease of approximately $120 million compared to Fiscal Year 2024[27] Cyber Incident Impact - The company estimates lost sales due to the cyber incident to be approximately $(350)-$(400) million[31] - The company estimates the cyber incident will impact adjusted EBITDA by approximately $(40)-$(50) million[31] - The company estimates a pre-tax and free cash flow loss of approximately $(65)-$(75) million due to the cyber incident[31] - The company estimates that the cyber incident will impact net (loss) income by $50 to $60 million[34] Strategic Focus - The company is focused on supporting customers and suppliers through solutions-oriented teamwork and transparent communication[22] - The company's strong cyber security protocol helped protect UNFI and partner personal information[22] - The company is on track to accelerate achievement of multi-year targets vs October 2024 targets[22]

Q2 2025 Financial Performance - Worldwide sales reached $23.7 billion, a 5.8% increase compared to Q2 2024, with operational sales growth of 4.6%[47] - U S sales increased by 7.8% to $13.5 billion in Q2 2025 from $12.6 billion in Q2 2024[47] - Adjusted earnings were $6.7 billion, and adjusted EPS was $2.77[49] - GAAP net earnings increased to $5.5 billion, a rise of 18.2%[49] Innovative Medicine - Innovative Medicine sales reached $15.202 billion, with operational growth of 3.8%[51] - Oncology sales grew by 22.3% operationally, reaching $6.312 billion[51] - Immunology sales declined by 16% operationally, totaling $3.993 billion, impacted by STELARA biosimilar competition[51] MedTech - MedTech sales were $8.541 billion, with operational growth of 6.1%[53] - Cardiovascular sales increased by 22.3% operationally, reaching $2.313 billion[53] - Orthopaedics sales decreased by 1.6% operationally, totaling $2.305 billion[53] Guidance - The company increased its operational sales guidance for 2025 to 4.8% and adjusted operational EPS guidance to 7.0% (midpoints)[62] - Operational sales are projected to be between $92.7 billion and $93.1 billion[62]

Consolidated Financial Performance - Net revenues for the second quarter of 2025 were $16792 million, a decrease of 5% from the first quarter of 2025 but an increase of 12% from the second quarter of 2024[2] - Net income applicable to Morgan Stanley for the second quarter of 2025 was $3539 million, a decrease of 18% from the first quarter of 2025 but an increase of 15% from the second quarter of 2024[2] - Earnings applicable to Morgan Stanley common shareholders for the second quarter of 2025 were $3392 million, a decrease of 18% from the first quarter of 2025 but an increase of 15% from the second quarter of 2024[2] - For the six months ended June 30, 2025, net revenues were $34531 million, a 15% increase compared to $30155 million for the six months ended June 30, 2024[2] - For the six months ended June 30, 2025, earnings applicable to Morgan Stanley common shareholders were $7549 million, a 22% increase compared to $6208 million for the six months ended June 30, 2024[2] Segment Performance - Institutional Securities net revenues for the second quarter of 2025 were $7643 million, a decrease of 15% from the first quarter of 2025 but an increase of 9% from the second quarter of 2024[2] - Wealth Management net revenues for the second quarter of 2025 were $7764 million, an increase of 6% from the first quarter of 2025 and a 14% increase from the second quarter of 2024[2] - Investment Management net revenues for the second quarter of 2025 were $1552 million, a decrease of 3% from the first quarter of 2025 but an increase of 12% from the second quarter of 2024[2] Balance Sheet and Capital - Total assets as of June 30, 2025, were $1353870 million, a 4% increase from March 31, 2025, and a 12% increase from June 30, 2024[5] - Total loans as of June 30, 2025, were $267395 million, a 3% increase from March 31, 2025, and a 12% increase from June 30, 2024[5] - Common equity as of June 30, 2025, was $98434 million, a 1% increase from March 31, 2025, and a 7% increase from June 30, 2024[5]

Financial Performance Highlights - Revenue reached $26.5 billion, a 4% year-over-year increase[2] - Net income was $7.1 billion, up 3% year-over-year[2] - Earnings per share (EPS) increased by 7% year-over-year to $0.89[2] - The return on average common shareholders' equity (ROE) was 100% and return on average tangible common shareholders' equity (ROTCE) was 134%[2] Balance Sheet Strength - Deposits totaled $20 trillion, a 5% increase year-over-year[2] - The common equity tier 1 (CET1) ratio was 115%, exceeding regulatory minimums[2] - Global liquidity sources (GLS) averaged $938 billion[2] Business Segment Growth - Consumer investment assets increased by 13% year-over-year to approximately $540 billion[9] - Global Banking average deposits grew 15% year-over-year to over $600 billion[10] - Global Wealth & Investment Management (GWIM) client balances increased 10% year-over-year to $44 trillion, with assets under management (AUM) up 13%[9] Artificial Intelligence and Innovation - The company is leveraging AI to drive efficiencies across various operations, including customer service, content summarization, and code generation[11] - Over 50 AI-enabled fraud detection models are in use[11] - The company has approximately 1,400 AI and machine learning patents granted and pending[11] Net Interest Income and Outlook - Net interest income (NII) increased by 7% year-over-year to $147 billion[14] - The company expects net interest income to be approximately $155 billion-$157 billion in 4Q25[51] Asset Quality - Total net charge-offs were $15 billion[12] - The allowance for loan and lease losses represented 117% of total loans and leases[65]

ASML reports €7.7 billion total net sales and €2.3 billion net income in Q2 2025 Agenda July 16, 2025 Page 2 Public • Investor key messages • Business summary • Outlook • Financial statements Full-year 2025 expected total net sales growth of around 15% with gross margin around 52% ASML 2025 Second-Quarter Veldhoven, the Netherlands July 16, 2025 Investor key messages July 16, 2025 Page 3 Investor key messages July 16, 2025 Page 4 Public • The semiconductor industry remains strong, driven by artificial intel ...

Transaction Overview - Mount Gibson Iron (MGX) is acquiring a 50% interest in the Central Tanami Project JV (CTPJV) from Northern Star Resources Ltd (NST)[10] - The acquisition cost is $50 million, plus adjustments[10] - The transaction is conditional and expected to be completed by March 31, 2026[26] Central Tanami Gold Project (CTPJV) - The CTPJV has a significant Mineral Resource of 1.6 million ounces of gold (100% basis)[10] - The project area covers approximately 5,700 square kilometers[10] - The Groundrush gold deposit within the CTPJV produced over 600,000 ounces of gold between 2001 and 2005 at 4 g/t Au[24,36] - The CTPJV includes a non-operating 1.2 Mtpa Carbon-in-Leach processing plant[24] Mount Gibson Iron (MGX) - MGX has substantial cash and investment reserves of $460 million as of March 31, 2025[16] - MGX has shipped over 40 million tonnes of iron ore since 2007 from Koolan Island[16] - MGX's Koolan Island mine is in its final 12-18 months of mine life[16] Valuation and Comparables - The acquisition multiple is $61/oz based on JORC 2012 Mineral Resource or $38/oz including historical (JORC 2004) estimates[29] - The average comparable transaction multiple is $174/oz[29]